Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orsolya Dohán

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Molecular and Cellular Endocrinology|April 6, 2004
Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyondOrsolya Dohán, Nancy Carrasco
Molecular Endocrinology (Baltimore, Md.)|January 28, 2006
Hydrocortisone and purinergic signaling stimulate sodium/iodide symporter (NIS)-mediated iodide transport in breast cancer cellsOrsolya Dohán, Antonio De la Vieja, Nancy Carrasco
Archives of Endocrinology and Metabolism|March 13, 2023
The master role of polarized NIS expression in regulating iodine metabolism in the human bodyBernadett Lévay, András Lantos, István Sinkovics, et al.
Molecular Endocrinology (Baltimore, Md.)|July 30, 2002
Na(+)/I(-) symporter activity requires a small and uncharged amino acid residue at position 395Orsolya Dohán, M Verónica Gavrielides, Christopher Ginter, et al.
BMC Cancer|January 12, 2007
Expression of the Na+/I- symporter (NIS) is markedly decreased or absent in gastric cancer and intestinal metaplastic mucosa of Barrett esophagusAron Altorjay, Orsolya Dohán, Anna Szilágyi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2007
The Na+/I symporter (NIS) mediates electroneutral active transport of the environmental pollutant perchlorateOrsolya Dohán, Carla Portulano, Cécile Basquin, et al.
Orvosi Hetilap|January 21, 2024
[Results of surgical treatment of papillary thyroid cancer with lymph node metastasis - review of our data in a 5-year period]Bernadett Lévay, Erika Tóth, Ilona Péter, et al.
Scientific Reports|July 15, 2026
Primary tumor resection prior to peptide receptor radionuclide therapy is associated with improved survival in metastatic gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysisSándor Orbán, Amir Makolli, Mahmoud Obeidat, et al.
Endocrine Reviews|February 18, 2003
The sodium/iodide Symporter (NIS): characterization, regulation, and medical significanceOrsolya Dohán, Antonio De la Vieja, Viktoriya Paroder, et al.
The Journal of Clinical Endocrinology and Metabolism|April 8, 2003
Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sectionsIrene L Wapnir, Matt van de Rijn, Kent Nowels, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Molecular and Cellular Endocrinology|April 6, 2004
Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyondOrsolya Dohán, Nancy Carrasco
Molecular Endocrinology (Baltimore, Md.)|January 28, 2006
Hydrocortisone and purinergic signaling stimulate sodium/iodide symporter (NIS)-mediated iodide transport in breast cancer cellsOrsolya Dohán, Antonio De la Vieja, Nancy Carrasco
Archives of Endocrinology and Metabolism|March 13, 2023
The master role of polarized NIS expression in regulating iodine metabolism in the human bodyBernadett Lévay, András Lantos, István Sinkovics, et al.
Molecular Endocrinology (Baltimore, Md.)|July 30, 2002
Na(+)/I(-) symporter activity requires a small and uncharged amino acid residue at position 395Orsolya Dohán, M Verónica Gavrielides, Christopher Ginter, et al.
BMC Cancer|January 12, 2007
Expression of the Na+/I- symporter (NIS) is markedly decreased or absent in gastric cancer and intestinal metaplastic mucosa of Barrett esophagusAron Altorjay, Orsolya Dohán, Anna Szilágyi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2007
The Na+/I symporter (NIS) mediates electroneutral active transport of the environmental pollutant perchlorateOrsolya Dohán, Carla Portulano, Cécile Basquin, et al.
Orvosi Hetilap|January 21, 2024
[Results of surgical treatment of papillary thyroid cancer with lymph node metastasis - review of our data in a 5-year period]Bernadett Lévay, Erika Tóth, Ilona Péter, et al.
Scientific Reports|July 15, 2026
Primary tumor resection prior to peptide receptor radionuclide therapy is associated with improved survival in metastatic gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysisSándor Orbán, Amir Makolli, Mahmoud Obeidat, et al.
Endocrine Reviews|February 18, 2003
The sodium/iodide Symporter (NIS): characterization, regulation, and medical significanceOrsolya Dohán, Antonio De la Vieja, Viktoriya Paroder, et al.
The Journal of Clinical Endocrinology and Metabolism|April 8, 2003
Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sectionsIrene L Wapnir, Matt van de Rijn, Kent Nowels, et al.
Pageof 2